BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

Overview

This phase 2b study is designed as multicentre, multinational, randomized, double blind, parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in subjects with excessive daytime sleepiness with Parkinson's disease.

Full Title of Study: “Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson’s Disease (PD).”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 28, 2019

Detailed Description

Phase 2b study will be conducted with the aim of investigating the efficacy and safety of three fixed doses of Bavisant (0.5, 1 and 3 mg/d) compared to placebo for the treatment of excessive daytime sleepiness (EDS) in subjects with Parkinson's disease.

Interventions

  • Drug: BEN-2001
    • Bavisant dihydrochloride monohydrate for oral use
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: BEN-2001, 0.5mg
    • Experimental treatment
  • Placebo Comparator: Placebo
    • Placebo comparator
  • Experimental: BEN-2001, 1.0mg
    • Experimental treatment
  • Experimental: BEN-2001, 3.0mg
    • Experimental treatment

Clinical Trial Outcome Measures

Primary Measures

  • Measurement of Sleepiness Using the Epworth Sleepiness Scale (ESS) at Baseline and Post Dose.
    • Time Frame: 6 weeks
    • Mean absolute change of Bavisant treatment groups in the Epworth Sleepiness Scale (ESS) from baseline to the end of the 6-week treatment period. The ESS score (sum of 8 item scores) ranges from 0 to 24 with higher score corresponding to higher average sleep propensity in daily life (higher daytime sleepiness). Eligibility determined based on ESS score of 13 and above.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects of either sex aged 50 to 80 years *Subjects with previous diagnosis of Parkinson's disease (following the UK Parkinson's disease society brain bank clinical diagnostic criteria)* – Subjects capable of understanding and complying with protocol requirements – Subjects with medical history of excessive daytime sleepiness Exclusion Criteria:

  • Subjects with excessive daytime sleepiness due to conditions other than Parkinson's disease (including narcolepsy) – Subjects with clinical evidence of depression with significant psychiatric comorbidities (Hamilton Rating Scale for Depression – HAM-D score greater than or equal to 17; with or without treatment) – Subjects with evidence of significant fatigue (Fatigue Severity Scale – FSS greater than or equal to 36 – Subjects with known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion. – Subjects with known allergies or hypersensitivity to Bavisant or any of its excipients. – Subjects who are pregnant or lactating.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • BenevolentAI Bio
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • William G Ondo, M.D, Principal Investigator, Methodist Neurological Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.